Quantitative Analysis of Immune Infiltrates in Primary Melanoma

Quantitative multiplex immunofluorescence and quantitative spatial analysis were used to evaluate the tumor microenvironment and allowed for the identification of a biomarker that correlated with survival in melanoma—the cytotoxic T lymphocyte-to-macrophage ratio. Novel methods to analyze the tumor microenvironment (TME) are urgently needed to stratify melanoma patients for adjuvant immunotherapy. Tumor-infiltrating lymphocyte (TIL) analysis, by conventional pathologic methods, is predictive but is insufficiently precise for clinical application. Quantitative multiplex immunofluorescence (qmIF) allows for evaluation of the TME using multiparameter phenotyping, tissue segmentation, and quantitative spatial analysis (qSA). Given that CD3+CD8+ cytotoxic lymphocytes (CTLs) promote antitumor immunity, whereas CD68+ macrophages impair immunity, we hypothesized that quantification and spatial analysis of macrophages and CTLs would correlate with clinical outcome. We applied qmIF to 104 primary stage II to III melanoma tumors and found that CTLs were closer in proximity to activated (CD68+HLA-DR+) macrophages than nonactivated (CD68+HLA-DR−) macrophages (P < 0.0001). CTLs were further in proximity from proliferating SOX10+ melanoma cells than nonproliferating ones (P < 0.0001). In 64 patients with known cause of death, we found that high CTL and low macrophage density in the stroma (P = 0.0038 and P = 0.0006, respectively) correlated with disease-specific survival (DSS), but the correlation was less significant for CTL and macrophage density in the tumor (P = 0.0147 and P = 0.0426, respectively). DSS correlation was strongest for stromal HLA-DR+ CTLs (P = 0.0005). CTL distance to HLA-DR− macrophages associated with poor DSS (P = 0.0016), whereas distance to Ki67− tumor cells associated inversely with DSS (P = 0.0006). A low CTL/macrophage ratio in the stroma conferred a hazard ratio (HR) of 3.719 for death from melanoma and correlated with shortened overall survival (OS) in the complete 104 patient cohort by Cox analysis (P = 0.009) and merits further development as a biomarker for clinical application. Cancer Immunol Res; 6(4); 481–93. ©2018 AACR.

[1]  I. Wistuba,et al.  Programmed cell death ligand 1 and tumor‐infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation , 2017, Cancer.

[2]  D. Neuberg,et al.  Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. , 2017, Blood.

[3]  D. Schuppan,et al.  Targeting myeloid cells in the tumor sustaining microenvironment. , 2017, Cellular immunology.

[4]  T. Lotti,et al.  Completion dissection or observation for sentinel‐node metastasis in melanoma , 2017, Dermatologic therapy.

[5]  Tuan Bui,et al.  Multiparametric immune profiling in HPV- oral squamous cell cancer. , 2017, JCI insight.

[6]  Souptik Barua,et al.  Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer , 2017, Nature Communications.

[7]  Adam A. Margolin,et al.  Quantitative Multiplex Immunohistochemistry Reveals Myeloid-Inflamed Tumor-Immune Complexity Associated with Poor Prognosis. , 2017, Cell reports.

[8]  P. Tan,et al.  Higher densities of Foxp3+ regulatory T cells are associated with better prognosis in triple-negative breast cancer , 2017, Breast Cancer Research and Treatment.

[9]  D. Guidolin,et al.  Spatial distribution of mast cells around vessels and glands in human gastric carcinoma , 2017, Clinical and Experimental Medicine.

[10]  Y. Gilad,et al.  Gene expression in local stroma reflects breast tumor states and predicts patient outcome , 2016, Scientific Reports.

[11]  J. Seidman,et al.  Fulminant Myocarditis with Combination Immune Checkpoint Blockade. , 2016, The New England journal of medicine.

[12]  A. Hauschild,et al.  Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. , 2016, The New England journal of medicine.

[13]  F. M. Marincola,et al.  Immunoscore and Immunoprofiling in cancer: an update from the melanoma and immunotherapy bridge 2015 , 2016, Journal of Translational Medicine.

[14]  Amy R. Peck,et al.  Validation of tumor protein marker quantification by two independent automated immunofluorescence image analysis platforms , 2016, Modern Pathology.

[15]  C. Figdor,et al.  T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. , 2016, Cancer research.

[16]  Mike J. Irwin,et al.  Computational pathology of pre-treatment biopsies identifies lymphocyte density as a predictor of response to neoadjuvant chemotherapy in breast cancer , 2016, Breast Cancer Research.

[17]  Bruce A. Corliss,et al.  Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis , 2016, Microcirculation.

[18]  M. Mihm,et al.  Tumour-infiltrating lymphocytes in melanoma prognosis and cancer immunotherapy. , 2016, Pathology.

[19]  Yu Shyr,et al.  Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy , 2016, Nature Communications.

[20]  Bernard A. Fox,et al.  Multispectral imaging of formalin-fixed tissue predicts ability to generate tumor-infiltrating lymphocytes from melanoma , 2015, Journal of Immunotherapy for Cancer.

[21]  B. Eynde,et al.  Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan. , 2015 .

[22]  B. J. Van den Eynde,et al.  Tumoral Immune Resistance Mediated by Enzymes That Degrade Tryptophan , 2015, Cancer Immunology Research.

[23]  M. Mihm,et al.  Reflections on the Histopathology of Tumor-Infiltrating Lymphocytes in Melanoma and the Host Immune Response , 2015, Cancer Immunology Research.

[24]  G. Natoli,et al.  Macrophages and cancer: from mechanisms to therapeutic implications. , 2015, Trends in immunology.

[25]  Sidra Nawaz,et al.  Beyond immune density: critical role of spatial heterogeneity in estrogen receptor-negative breast cancer , 2015, Modern Pathology.

[26]  E. Gonzalez-Billalabeitia,et al.  Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer , 2014, Breast Cancer Research.

[27]  Chichung Wang,et al.  Multiplexed immunohistochemistry, imaging, and quantitation: a review, with an assessment of Tyramide signal amplification, multispectral imaging and multiplex analysis. , 2014, Methods.

[28]  R. Emerson,et al.  PD-1 blockade induces responses by inhibiting adaptive immune resistance , 2014, Nature.

[29]  L. D. Hall,et al.  Dissection of immune gene networks in primary melanoma tumors critical for antitumor surveillance of patients with stage II-III resectable disease. , 2014, The Journal of investigative dermatology.

[30]  Jérôme Galon,et al.  [Intratumoral immune microenvironment and survival: the immunoscore]. , 2014, Medecine sciences : M/S.

[31]  Lee B. Smith,et al.  Intratubular germ cell neoplasia of the human testis: heterogeneous protein expression and relation to invasive potential , 2014, Modern Pathology.

[32]  M. Takeya,et al.  Clinical significance of macrophage heterogeneity in human malignant tumors , 2013, Cancer science.

[33]  J. Galon,et al.  [Intratumoral immune microenvironment and survival: the immunoscore]. , 2014, Medecine sciences : M/S.

[34]  D. Chen,et al.  Spatial organization of dendritic cells within tumor draining lymph nodes impacts clinical outcome in breast cancer patients , 2013, Journal of Translational Medicine.

[35]  H. Schreiber,et al.  Innate and adaptive immune cells in the tumor microenvironment , 2013, Nature Immunology.

[36]  A. Ladányi.  [Prognostic value of tumor-infiltrating immune cells in melanoma]. , 2013, Magyar onkologia.

[37]  S. Jalkanen,et al.  Type and location of tumor‐infiltrating macrophages and lymphatic vessels predict survival of colorectal cancer patients , 2012, International journal of cancer.

[38]  R. Scolyer,et al.  Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  C. Slingluff,et al.  Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma. , 2012, Cancer research.

[40]  G. Barbieri,et al.  Effects of human leukocyte antigen (HLA)-DR engagement on melanoma cells. , 2011, International journal of oncology.

[41]  Jeffrey E Gershenwald,et al.  Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[42]  S. Steinberg,et al.  Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer , 2010, Cancer Immunology, Immunotherapy.

[43]  Lunxu Liu,et al.  The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time , 2010, BMC Cancer.

[44]  Jeffrey E Gershenwald,et al.  Final version of 2009 AJCC melanoma staging and classification. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  H. Møller,et al.  Macrophage markers in serum and tumor have prognostic impact in American Joint Committee on Cancer stage I/II melanoma. , 2009, Journal of Clinical Oncology.

[46]  M. Mihm,et al.  Progress in melanoma histopathology and diagnosis. , 2009, Hematology/oncology clinics of North America.

[47]  A. Marghoob,et al.  Histologic classification of tumor-infiltrating lymphocytes in primary cutaneous malignant melanoma. A study of interobserver agreement. , 2001, American journal of clinical pathology.

[48]  Kristi Kincaid,et al.  M-1/M-2 Macrophages and the Th1/Th2 Paradigm1 , 2000, The Journal of Immunology.

[49]  R. Horansky,et al.  Macrophages can recognize and kill tumor cells bearing the membrane isoform of macrophage colony-stimulating factor. , 1996, Blood.

[50]  Natale Cascinelli,et al.  Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma , 1996, Cancer.

[51]  P. Colloby,et al.  Is poor prognosis really related to HLA‐DR expression by malignant melanoma cells? , 1992, Histopathology.

[52]  M N Bobrow,et al.  Catalyzed reporter deposition, a novel method of signal amplification. II. Application to membrane immunoassays. , 1991, Journal of immunological methods.

[53]  R. Keist,et al.  Mechanisms of macrophage‐mediated tumor cell killing: A comparative analysis of the roles of reactive nitrogen intermediates and tumor necrosis factor , 1990, International journal of cancer.

[54]  T. Harris,et al.  Catalyzed reporter deposition, a novel method of signal amplification. Application to immunoassays. , 1989, Journal of immunological methods.

[55]  S. Rosenberg,et al.  Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. , 1989, Cancer research.

[56]  W. Clark,et al.  The role of lymph node dissection for clinical stage I malignant melanoma of intermediate thickness (1.51—3.99 mm) , 1985, Cancer.